Clinicopathologic and Molecular Characterization of Colorectal Cancer in Patients Aged ≥80 years

80岁及以上患者结直肠癌的临床病理及分子特征

阅读:1

Abstract

INTRODUCTION: With rapid global aging, older colorectal cancer (CRC) patients are increasing, yet their clinical and molecular characteristics remain inadequately characterized. This comparative study systematically analyzed clinical and molecular characteristics of older CRC patients aged 60-80 years and those aged ≥80 years to provide evidence for individualized treatment strategies. METHODS: Older CRC patients who underwent radical surgery at Peking University Third Hospital from October 2015 to June 2023 were retrospectively included. Patients were categorized as older-age group (≥80 years, n=214) and younger-age group (≥60 and <80 years, n=958). Clinicopathological characteristics and disease-free survival (DFS) were analyzed. Transcriptome sequencing and analysis was performed on 244 primary CRC tissues (53 older-age and 191 younger-age). RESULTS: Among 1172 patients, the older-age group demonstrated distinctive clinical features: reduced chemotherapy receipt, elevated CEA levels, more right-sided tumors, more mucinous adenocarcinomas, larger tumor size, and higher mismatch repair deficiency (dMMR) prevalence (all P<0.05). DFS was significantly shorter in the older-age group (P<0.001), with age ≥80 years identified as an independent risk factor (HR=1.530, 95% CI: 1.022-2.290, P=0.039). Transcriptomic analysis revealed unique biological characteristics in the older-age group: upregulation of neural regulation and extracellular matrix remodeling pathways, downregulated immune responses with increased M2 macrophage infiltration, and enrichment of CMS1 and CMS4 molecular subtypes. CONCLUSION: CRC patients aged ≥80 years exhibit higher dMMR rates and shorter DFS, with molecular features of immunosuppression, ECM remodeling, and enhanced neural-tumor interactions, challenging the assumption of slow CRC progression in very older patients. These findings provide basis for personalized treatment strategies in this underrepresented and growing population.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。